Perimeter Medical Imaging AI (OTCMKTS:PYNKF) and Cerus (NASDAQ:CERS) Head to Head Review

Perimeter Medical Imaging AI (OTCMKTS:PYNKF) and Cerus (NASDAQ:CERS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends.

Insider & Institutional Ownership

78.4% of Cerus shares are held by institutional investors. 3.4% of Cerus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Perimeter Medical Imaging AI and Cerus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Perimeter Medical Imaging AI	N/A	N/A	N/A
Cerus	-14.15%	-44.27%	-11.54%

Analyst Recommendations

This is a summary of recent ratings and target prices for Perimeter Medical Imaging AI and Cerus, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perimeter Medical Imaging AI	0	0	0	0	N/A
Cerus	0	1	2	0	2.67

Cerus has a consensus price target of $3.83, indicating a potential upside of 81.67%. Given Cerus’ higher possible upside, analysts plainly believe Cerus is more favorable than Perimeter Medical Imaging AI.

Valuation & Earnings

This table compares Perimeter Medical Imaging AI and Cerus’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perimeter Medical Imaging AI	N/A	N/A	N/A	N/A	N/A
Cerus	$169.98 million	2.30	-$37.49 million	($0.17)	-12.41

Perimeter Medical Imaging AI has higher earnings, but lower revenue than Cerus.

Summary

Cerus beats Perimeter Medical Imaging AI on 5 of the 8 factors compared between the two stocks.

About Perimeter Medical Imaging AI

Perimeter Medical Imaging AI, Inc., a medical technology company, provides advanced imaging tools that address unmet medical needs. The company offers Perimeter S-Series optical coherence tomography (OCT) imaging system that delivers resolution margin visualization of excised tissue specimens in the operating room. It also develops Perimeter B-series OCT with ImgAssist artificial intelligence technology for patients undergoing breast conservation surgery. In addition, the company offers proprietary image library and consumable specimen containers to hospitals and cancer surgery centers. Perimeter Medical Imaging AI, Inc. is headquartered in Toronto, Canada.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.